Drug Discovery Today
October 1, 2025
Noor-Ul-Huda Butt, Sultan Nacak Baytas
4 citations
Indole-based compounds serve as versatile pharmacophores across anticancer, antiviral, neurological, antimicrobial, and metabolic therapies. This review systematically analyses FDA-approved, withdrawn, and investigational indole-containing drugs over the past decade, focusing on evolving clinical outcomes, regulatory decisions, and therapeutic repositioning. It explores the shift from cytotoxic...
Drug Discovery Today
June 1, 2025
Sara Castanheira, Catarina Vale Gomes, Joana Bicker et al.
9 citations
The discovery of the rapid antidepressant action of ketamine accelerated the identification of new molecules that are associated with fast and prolonged relief of depressive symptoms. As a result, a new group of antidepressants have emerged, some of them already approved for clinical use, classified as rapid-acting antidepressant drugs (RAADs). Potentiation of brain-derived neurotrophic factor...
Drug Discovery Today
December 1, 2023
Taeho Greg Rhee, Pasha A. Davoudian, Gerard Sanacora et al.
20 citations
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT),...
Drug Discovery Today
February 1, 2023
J. Johnston, Maximillian Greenwald, Ioline D. Henter et al.
64 citations
Well-established animal models of depression have described a proximal relationship between stress and central nervous system (CNS) inflammation – a relationship mirrored in the peripheral inflammatory biomarkers of individuals with depression. Evidence also suggests that stress-induced proinflammatory states can contribute to the neurobiology of treatment-resistant depression. Interestingly,...